Mycophenolate mofetil
Canadian Agency for Drugs and Technologies in Health
Record ID 32006000854
English
Authors' objectives:
The aim of this study was to summarize the available information on the use of Mycophenolate mofetil (MMF) (trade mark CellCept, manufactured by Roche Pharmaceuticals, Inc.).
Authors' recommendations:
The evidence that shows MMF to be an effective therapy for psoriasis comes from small clinical trials and several case reports. It would be optimal to have evidence from large, randomized, controlled clinical trials to establish the efficacy and safety of this emerging therapy. Given that severe psoriasis affects about one million Canadians, the monthly cost of C$560 per patient may have a significant impact on the health care system. In addition, there is no approved standard dosage or optimal treatment duration with MMF. All this suggests cost implications and complexity in prescription decisions.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
http://www.cadth.ca/
Year Published:
2006
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Costs and Cost Analysis
- Mycophenolic Acid
- Psoriasis
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drug and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.